Education
About Us
Working with TipRanks
Follow Us
XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
XRTX Stock Chart & Stats
C$0.91
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.91
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$0.91 - C$2.71
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$5.26M
Enterprise ValueC$3.28M
Total Cash (Recent Filing)C$1.06M
Total Debt (Recent Filing)C$80.47K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 12, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding5,212,218
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$0.91 and its highest was C$2.71 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.26M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2025 which is in 15 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported -C$0.266 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.266.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate is -0.23.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 5,212,218 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.266 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc (XRTX) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies to treat progressive kidney disease, diabetes, and cardiovascular disease. The company focuses on developing innovative drug therapies that target uric acid as a primary cause of these chronic diseases. XORTX's lead product candidate, XORLO, is aimed at treating autosomal dominant polycystic kidney disease (ADPKD), with additional applications being explored for other forms of kidney disease and metabolic syndrome.
Technical Analysis
Quest Pharmatech
―
Algernon Pharmaceuticals
―
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Marvel Biosciences Corp
―
Options Prices
Currently, No data available
---